Busslinger, Sarah D.
Mapanao, Ana Katrina
Kegler, Kristel
Bernhardt, Peter
Flühmann, Fabienne
Fricke, Julia
Zeevaart, Jan Rijn
Köster, Ulli
van der Meulen, Nicholas P.
Schibli, Roger
Müller, Cristina http://orcid.org/0000-0001-9357-9688
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_188978)
the European Union's Horizon 2020 (884104)
Swiss Cancer Research (KFS-5624-08-2022)
Swedish Cancer Society (Swedish Cancer Society)
ITM Medical Isotopes GmbH, Munich (ITM Medical Isotopes GmbH, Munich)
PSI - Paul Scherrer Institute
Article History
Received: 29 April 2024
Accepted: 30 June 2024
First Online: 24 July 2024
Declarations
:
: This study was performed in agreement with the national law and PSI-internal guidelines of radiation safety protection. In vivo experiments were approved by the local veterinarian department and ethics committee and conducted in accordance with the Swiss law of animal protection.
: The University Hospital Basel and the Paul Scherrer Institute have filed a patent with regard to [<sup>161</sup>Tb]Tb-DOTA-LM3. R. Schibli, N. van der Meulen and C. Müller are listed as co-inventors on the patent application.